Drugs / ALD-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01774097 | Jun 2013 → Aug 2016 | intermittent vascular claudication, peripheral arterial disease | The University of Texas Health Science Center, Houston | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALD-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01774097 ↗ |
| Modality | Cell therapy | “autologous bone marrow-derived aldehyde dehydrogenase bright (ALDHbr) cells” PMID 28209728 ↗ Feb 2017 |
| Route | Intramuscular | “Participants will receive ALD-301 via intramuscular injection” NCT01774097 ↗ |